Characterization and Management of Sevabertinib induced Diarrhea in the SOHO 1 study

This analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea was frequently observed but generally low grade, short in duration, and manageable with standard supportive care and dose modifications. Findings also suggest that prior therapies and drug exposure levels may influence the risk of more severe diarrhea, providing useful context for clinical management.